Kuldeep Neote
Chief Executive Officer Diadem Biotherapeutics
Dr. Kuldeep Neote is the Chief Executive Officer of Diadem Biotherapeutics, a company developing engineered extracellular vesicle therapies for cancer and autoimmune diseases. He previously served as Vice President of External Innovation at Eli Lilly and Company, where he led new venture initiatives focused on precision and genomic medicine. Earlier in his career, he held leadership roles at Johnson & Johnson Innovation and worked as a discovery scientist at Pfizer and Genentech, contributing to pioneering chemokine receptor research. Dr. Neote earned his Ph.D. in Human and Molecular Genetics from the University of Toronto and has spent more than 25 years advancing drug discovery, oncology, and immunology innovation.
Seminars
- Breaking down major cost drivers including CMC development, GMP manufacturing scale-up, patient recruitment, and long-term safety monitoring requirements
- Reducing inefficiencies through smarter trial design, including adaptive protocols, streamlined endpoints, and biomarker-informed patient selection
- Leveraging scalable manufacturing and early regulatory alignment to minimise delays, rework, and costly late-stage development changes
